Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immunomodulation by anticancer chemotherapy: More is not always better (review)
Autore:
Zagozdzon, R; Golab, J;
Indirizzi:
Med Univ Warsaw, Ctr Biostruct, Dept Immunol, PL-02004 Warsaw, Poland Med Univ Warsaw Warsaw Poland PL-02004 Immunol, PL-02004 Warsaw, Poland Med Univ Warsaw, Inst Transplantat, Dept Immunol & Inernal Dis, Warsaw, Poland Med Univ Warsaw Warsaw Poland ept Immunol & Inernal Dis, Warsaw, Poland
Titolo Testata:
INTERNATIONAL JOURNAL OF ONCOLOGY
fascicolo: 2, volume: 18, anno: 2001,
pagine: 417 - 424
SICI:
1019-6439(200102)18:2<417:IBACMI>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; LOW-DOSE CYCLOPHOSPHAMIDE; COLONY-STIMULATING FACTOR; KILLER-CELL ACTIVITY; STABILIZING ANTINEOPLASTIC AGENT; ADRIAMYCIN PLUS INTERLEUKIN-2; MURINE PERITONEAL-MACROPHAGES; RECOMBINANT INTERFERON-GAMMA; NITRIC-OXIDE PRODUCTION; HUMAN OVARIAN-CANCER;
Keywords:
low-dose chemotherapy; cyclophosphamide; doxorubicin; cisplatin; paclitaxel; 5-fluorouracil;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
112
Recensione:
Indirizzi per estratti:
Indirizzo: Golab, J Med Univ Warsaw, Ctr Biostruct, Dept Immunol, Chalubinskiego 5, PL-02004 Warsaw, Poland Med Univ Warsaw Chalubinskiego 5 Warsaw Poland PL-02004 , Poland
Citazione:
R. Zagozdzon e J. Golab, "Immunomodulation by anticancer chemotherapy: More is not always better (review)", INT J ONCOL, 18(2), 2001, pp. 417-424

Abstract

Chemotherapeutics are the mainstay of the majority of antitumor treatment strategies. These agents are usually administered at or near maximum tolerated doses resulting in frequent dramatic toxicities that compromise the quality of life and the immune response towards microbial pathogens. A number of observations suggest that low-dose treatment with chemotherapeutics is sometimes equal or even superior to high-dose chemotherapy. The efficacy of low-dose chemotherapy can be at least partly explained by the regulation ofthe antitumor immune response. The immunomodulatory effects of some chemotherapeutics might be further potentiated by combinations with selected biological response modifiers such as recombinant cytokines (IL-2, TNF, IL-12). The effectiveness of such treatment combinations have already proved effective in preclinical animal models. However, the efficacy in humans is stillto be demonstrated in rationally designed clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 23:28:39